For Patients Undergoing Surgery for Advanced Gastric Cancer, Somatostatin May Improve Outcomes

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal World Journal of Gastroenterology, postoperative treatment with somatostatin decreases the volume and duration of surgical drainage and associated complication following D2 lymphadenectomy and vagina vasorum dissection in patients with advanced gastric cancer.

For the prospective, single-blind, placebo-controlled study, researchers randomly assigned 120 patients at First Affiliated Hospital of Sun Yat-Sen University in China to receive either somatostatin for 5 to 7 days beginning 6 hours after surgery or normal saline.

Results showed no significant difference in overall incidence of complications between the two groups; however, patients that received somatostatin experienced less peritoneal effusion compared with the control group (1.6% versus 10.2%; P < 0.05).

In addition, no significant differences were observed in the incidence of postoperative pancreatic dysfunction and chylous fistula. Significant differences were observed in the amylase concentration in drainage fluid and volume and duration of drainage, chylous fistula, peritoneal drainage, and gastric tube drainage.

The findings suggest that somatostatin may improve the safety of D2 lymphadenectomy and vagina vasorum dissection in patients with advanced gastric cancer, as well as decrease postoperative complication improve recovery.

For Patients Undergoing Surgery for Advanced Gastric Cancer, Somatostatin May Improve Outcomes
Postoperative treatment with somatostatin decreases the volume and duration of drainage
The authors aim to study the effect of somatostatin in patients with advanced gastric cancer who received D2 lymphadenectomy and vagina vasorum dissection. Postoperative somatostatin reduces volume and duration of surgical drainage and related complications. Somatostatin may improve safety of gastric cancer surgery, reducing postoperative complications and promoting recovery.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs